Biogen Idec’s BG-12 Results Up The Ante In The Oral MS Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The competitive profile of Biogen Idec Inc.’s BG-12 in the highly coveted and burgeoning market for oral multiple sclerosis drugs got a big boost April 21 with the release of better-than-expected additional monotherapy data from the Phase III DEFINE study.
You may also be interested in...
Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More
Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.
Top-Line Results For Sanofi/Genzyme's MS Drug Lemtrada Leave Investors Wanting More
Alemtuzumab scores a win in reducing relapse rates, but doesn't best interferon beta-1a at preventing disability in first of two crucial Phase III studies due to report this year.
Novartis Gilenya Approved With Advisory Panel-Enhanced REMS
FDA follows the advice of its Peripheral and Central Nervous System Drugs Advisory Committee to ask doctors to do a range of testing and monitoring when they prescribe the MS drug.